Vical is working on a dengue treatment. However the company is faced hardship with other pipeline ventures. Don't know if they will jump into zika territory
From vicals website:
"Tetravalent dengue vaccine (TVDV) is a plasmid DNA-based infectious disease vaccine in clinical development in humans for the prevention of all 4 dengue virus serotypes. Vical manufactured TVDV under contract with the Naval Medical Research Center, who has conducted Phase 1 testing of this vaccine. TVDV utilizes Vical’s proprietary adjuvant formulation, Vaxfectin®, to increase immune responses."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.